TG Therapeutics to Join Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024

TG Therapeutics, Inc. (NASDAQ: TGTX) has announced that its Chairman and CEO, Michael S. Weiss, will be attending the Goldman Sachs 45th Annual Global Healthcare Conference. This significant event is set to take place at the Loews Miami Beach Hotel in Miami Beach, Florida, from June 10 to June 13, 2024. Mr. Weiss is scheduled to participate in a fireside chat on Tuesday, June 11, 2024, at 1:20 PM ET. The chat will be available for live webcast on the company’s website under the Events page in the Investors & Media section.

TG Therapeutics is a biopharmaceutical company that is fully integrated and operates at a commercial stage. The company’s primary focus is on acquiring, developing, and commercializing innovative treatments for B-cell diseases. Their research pipeline includes several investigational drugs. Notably, TG Therapeutics has achieved U.S. FDA approval for BRIUMVI® (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis (RMS). This approval encompasses clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Moreover, BRIUMVI has also received approval from the European Commission and the Medicines and Healthcare Products Regulatory Agency in the United Kingdom for treating adult patients with RMS who have active disease, defined by clinical or imaging features.

BRIUMVI® is a registered trademark of TG Therapeutics, Inc. The company maintains a presence on social media through X (formerly Twitter) and LinkedIn, where they share updates and information.

Company Details
- Event: Goldman Sachs 45th Annual Global Healthcare Conference
- Location: Loews Miami Beach Hotel, Miami Beach, Florida
- Dates: June 10-13, 2024
- Fireside Chat Date: June 11, 2024
- Time: 1:20 PM ET

About TG Therapeutics
- Focus: B-cell diseases
- Stage: Fully integrated, commercial
- Key Product: BRIUMVI® (ublituximab-xiiy)
- FDA Approval: For adult patients with relapsing forms of multiple sclerosis (RMS)
- Conditions: Clinically isolated syndrome, relapsing-remitting disease, active secondary progressive disease
- European Commission Approval: For RMS with active disease
- UK Approval: Medicines and Healthcare Products Regulatory Agency for RMS with active disease

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!